Verona validation of the DAAE score, a tool for estimating risk of clinical disease progression in people with multiple sclerosis
Tom Fuchs(Amsterdam Neuroscience), Massimiliano Calabrese(University of Verona), Menno M. Schoonheim(Amsterdam Neuroscience), Julia R. Jelgerhuis(Amsterdam Neuroscience), Bianca Weinstock‐Guttman(Jacobs Institute), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), Eva Strijbis(Amsterdam Neuroscience), Robert Zivadinov(Yale University), Stefano Ziccardi(University of Verona)
Cited by 2
Related Papers
Loss of ‘Small-World’ Networks in Alzheimer's Disease: Graph Analysis of fMRI Resting-State Functional Connectivity
|PLoS ONE|2010|621
Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis
|Archives of Neurology|2009|547
Deep gray matter volume loss drives disability worsening in multiple sclerosis
|Annals of Neurology|2018|441
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative
|Nature Reviews Neurology|2016|413
Exploring the origins of grey matter damage in multiple sclerosis
|Nature reviews. Neuroscience|2015|410